Advanced pancreatic neuroendocrine tumor patient treated with everolimus – case report Case report
Article Sidebar
Main Article Content
Abstract
The increasing incidence of gastroenteropancreatic neuroendocrine tumors is caused not exclusively by increasing number of new cases, but also by improved diagnostics. Proper diagnosis and evaluation of tumor differentiation lead to disease prognosis and selection of optimal treatment. Presented clinical case of pancreatic neuroendocrine tumor patient treated with everolimus proves the efficacy of targeted therapy.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. O’Toole D., Salazar R., Falconi M. et al.: Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006; 84: 189-195.
3. Yao J.C., Hassan M., Phan A. et al.: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008 Jun 20; 26(18): 3063-72.
4. Yao J.C., Shah M.H., Ito T. et al.: Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N. Engl. J. Med. 2011; 364: 514-23.
5. 2012 ENETS Consensus Guidelines. Neuroendocrinology 2012; 95: 120-134.
6. Motzer R.J., Escudier B., Oudard S. et. al. Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma. Cancer 2010 Sep; 116(18): 4256-4265.